TWI857119B - 治療癌症之方法 - Google Patents

治療癌症之方法 Download PDF

Info

Publication number
TWI857119B
TWI857119B TW109126973A TW109126973A TWI857119B TW I857119 B TWI857119 B TW I857119B TW 109126973 A TW109126973 A TW 109126973A TW 109126973 A TW109126973 A TW 109126973A TW I857119 B TWI857119 B TW I857119B
Authority
TW
Taiwan
Prior art keywords
dose
pharmaceutically acceptable
acceptable salt
cfg920
patient
Prior art date
Application number
TW109126973A
Other languages
English (en)
Chinese (zh)
Other versions
TW202120086A (zh
Inventor
向陽 呂
張瑞鵬
勇 岳
張敏華
Original Assignee
香港商來凱有限公司
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 香港商來凱有限公司 filed Critical 香港商來凱有限公司
Publication of TW202120086A publication Critical patent/TW202120086A/zh
Application granted granted Critical
Publication of TWI857119B publication Critical patent/TWI857119B/zh

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/415—1,2-Diazoles
    • A61K31/4155—1,2-Diazoles non condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/444—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring heteroatom, e.g. amrinone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
    • A61K31/573—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone substituted in position 21, e.g. cortisone, dexamethasone, prednisone or aldosterone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Oncology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Steroid Compounds (AREA)
TW109126973A 2019-08-08 2020-08-07 治療癌症之方法 TWI857119B (zh)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
CN2019099754 2019-08-08
WOPCT/CN2019/099754 2019-08-08

Publications (2)

Publication Number Publication Date
TW202120086A TW202120086A (zh) 2021-06-01
TWI857119B true TWI857119B (zh) 2024-10-01

Family

ID=72234946

Family Applications (1)

Application Number Title Priority Date Filing Date
TW109126973A TWI857119B (zh) 2019-08-08 2020-08-07 治療癌症之方法

Country Status (12)

Country Link
US (2) US20210038578A1 (https=)
EP (1) EP4009969A1 (https=)
JP (1) JP7526783B2 (https=)
KR (1) KR20220047589A (https=)
CN (1) CN114080225A (https=)
AU (1) AU2020327022B2 (https=)
BR (1) BR112022001508A2 (https=)
CA (1) CA3148115A1 (https=)
IL (1) IL289811A (https=)
MX (1) MX2022001450A (https=)
TW (1) TWI857119B (https=)
WO (1) WO2021026454A1 (https=)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7010330B1 (en) 2003-03-01 2006-03-07 Theta Microelectronics, Inc. Power dissipation reduction in wireless transceivers
US20250032504A1 (en) * 2021-11-27 2025-01-30 Transthera Sciences (Nanjing), Inc. Novel application of kinase inhibitor
US20250177352A1 (en) 2022-03-14 2025-06-05 Laekna Limited Combination treatment for cancer

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN109674801A (zh) * 2013-10-01 2019-04-26 诺华股份有限公司 组合

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2601675B1 (fr) 1986-07-17 1988-09-23 Rhone Poulenc Sante Derives du taxol, leur preparation et les compositions pharmaceutiques qui les contiennent
GB2265624B (en) 1992-03-31 1995-04-19 British Tech Group 17-substituted steroids useful in cancer treatment
MA23823A1 (fr) 1995-03-27 1996-10-01 Aventis Pharma Sa Nouveaux taxoides, leur preparation et les compositions qui les contiennent
ATE273695T1 (de) 2000-06-28 2004-09-15 Smithkline Beecham Plc Nassvermahlung
US7709517B2 (en) 2005-05-13 2010-05-04 The Regents Of The University Of California Diarylhydantoin compounds
LT2656842T (lt) 2006-03-27 2016-09-26 The Regents Of The University Of California Androgeno receptoriaus moduliatorius, skirtas prostatos vėžio ir su androgeno receptoriumi susijusių ligų gydymui
UY30892A1 (es) 2007-02-07 2008-09-02 Smithkline Beckman Corp Inhibidores de la actividad akt
US20110288142A1 (en) * 2009-01-30 2011-11-24 Chen Pingyun Y CRYSTALLINE N--5-chloro-4-(4-chloro-1-methyl-1H-pyrazol-5-yl)-2-thiophenecarboxamide hydrochloride
UY32730A (es) * 2009-06-26 2011-01-31 Novartis Ag Inhibidores de cyp17
AR078793A1 (es) 2009-10-27 2011-12-07 Orion Corp Derivados de carboxamidas no esteroidales y acil hidrazona moduladores de receptores androgenicos de tejido selectivo (sarm), composiciones farmaceuticas que los contienen y uso de los mismos en el tratamiento del cancer de prostata entre otros
RU2014154009A (ru) * 2012-06-06 2016-08-10 Новартис Аг Комбинация ингибитора 17-альфа-гидроксилазы (с17,20-лиазы) и специфического ингибитора pi-3k для лечения онкологического заболевания
US10265329B2 (en) * 2015-03-06 2019-04-23 The Cleveland Clinic Foundation Altering steroid metabolism for treatment of steroid-dependent disease

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN109674801A (zh) * 2013-10-01 2019-04-26 诺华股份有限公司 组合

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
期刊 Benjamin L Maughan et al., Androgen pathway resistance in prostate cancer and therapeutic implications Expert Opin Pharmacother., 16(10), 2015, 1521–1537.;期刊 Maria De Santis and Fred Saad Practical Guidance on the Role of Corticosteroids in the Treatment of Metastatic Castration-resistant Prostate Cancer Prostate Cancer, Urology, Volume 96, October 2016 156-164. *
期刊 Maria De Santis and Fred Saad Practical Guidance on the Role of Corticosteroids in the Treatment of Metastatic Castration-resistant Prostate Cancer Prostate Cancer, Urology, Volume 96, October 2016 156-164.

Also Published As

Publication number Publication date
US20250090514A1 (en) 2025-03-20
JP2022543679A (ja) 2022-10-13
AU2020327022A8 (en) 2022-06-30
WO2021026454A1 (en) 2021-02-11
AU2020327022A1 (en) 2022-02-10
KR20220047589A (ko) 2022-04-18
AU2020327022B2 (en) 2025-12-18
BR112022001508A2 (pt) 2022-07-12
MX2022001450A (es) 2022-04-20
TW202120086A (zh) 2021-06-01
JP7526783B2 (ja) 2024-08-01
EP4009969A1 (en) 2022-06-15
CN114080225A (zh) 2022-02-22
CA3148115A1 (en) 2021-02-11
US20210038578A1 (en) 2021-02-11
IL289811A (en) 2022-03-01

Similar Documents

Publication Publication Date Title
US20250090514A1 (en) Method of treating cancer
US20240180906A1 (en) Combination of Talazoparib and an Anti-Androgen for the Treatment of DDR Gene Mutated Metastatic Castration-Sensitive Prostate Cancer
EP4633629A1 (en) Combination of talazoparib and enzalutamide in the treatment of metastatic castration-resistant prostate cancer
JP2017521468A (ja) 組み合わせ療法
EA049014B1 (ru) Способ лечения рака
US20240335440A1 (en) Combination therapy comprising a pkc inhibitor and a c-met inhibitor
US20250170146A1 (en) Niraparib and abiraterone acetate plus prednisone to improve clinical outcomes in patients with metastatic castration-resistant prostate cancer and hrr alterations
JP2026000999A (ja) 重度の肝障害を有する対象における非転移性去勢抵抗性前立腺癌の治療のためのアンドロゲン受容体阻害剤
HK40098285A (zh) 用於治疗ddr基因突变转移性去势敏感性前列腺癌的他拉唑帕尼与抗雄激素的组合
HK40087811A (zh) 用於治疗具有严重肝损伤的受试者的非转移性去势抵抗性前列腺癌的雄激素受体抑制剂
AU2023356291A1 (en) Methods of treating estrogen receptor-mediated disorders
CN117098535A (zh) 用于治疗ddr基因突变转移性去势敏感性前列腺癌的他拉唑帕尼与抗雄激素的组合
TW202339748A (zh) 使用經取代之嘧啶-4(3h)-酮之治療方法
AU2021432315A1 (en) Treating cancer in patient having co-occurring genetic alteration in fgfr2 and a cancer driver gene
HK1204976B (en) Pharmaceutical combinations comprising a b-raf inhibitor, an egfr inhibitor and optionally a pi3k-alpha inhibitor